Alpha-MSH vs Splenin

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Spleen-derived tetrapeptide bioregulator; normalizes leukocyte and platelet production; modulates splenic immune cell activity

Splenin is a synthetic tripeptide (Lys-Glu-Asp, KED) classified as a Khavinson-class bioregulator peptide targeted at splenic and immune tissue, investigated for immunomodulatory and cytoprotective properties through proposed gene expression regulatory mechanisms in lymphoid and hematopoietic cell populations. Like other short Khavinson bioregulator peptides, splenin is proposed to modulate gene expression in target immune cells via epigenetic mechanisms, with published research on the class demonstrating that ultrashort peptides can influence differentiation of stem and progenitor cells and regulate gene activity in aging tissues. Research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in neurodegeneration models and demonstrated peptide regulation of cell differentiation in stem cell preparations, providing the class-level mechanistic context within which splenin is proposed to act on immune tissue. Splenin has no FDA approval or regulatory approval in any major jurisdiction outside Russia; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.